Land: Kanada
Sprache: Englisch
Quelle: Health Canada
DESLORATADINE
BAYER INC
R06AX27
DESLORATADINE
5MG
TABLET
DESLORATADINE 5MG
ORAL
10/20/30/100
OTC
SECOND GENERATION ANTIHISTAMINES
Active ingredient group (AIG) number: 0143961001; AHFS:
APPROVED
2014-11-07
_Lesen Sie das vollständige Dokument _ _ Desloratadine Syrup 0.5 mg/mL> _ _Page 1 of 40 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION AERIUS® Desloratadine Tablet, 5mg, Oral USP AERIUS® KIDS Desloratadine Syrup, 0.5 mg/mL Oral Professed Standard Histamine H1-Receptor Antagonist Bayer Inc. 2920 Matheson Blvd. East Mississauga, ON L4W 5R6 Date of Revision: October 11, 2022 Submission Control Number: 263344 ®TM see www.bayer.ca/tm-mc _ _ _ _ _ Desloratadine Syrup 0.5 mg/mL> _ _Page 2 of 40_ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS ........................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 4 1 INDICATIONS.................................................................................................................... 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics................................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.................................................................. 4 4 DOSAGE AND ADMINISTRATION ...................................................................................... 4 4.1 Dosing Considerations.................................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment................................................................. 4 4.3 Administration ............................................................................................................... 5 4.4 Mi